tofacitinib and Precursor-Cell-Lymphoblastic-Leukemia-Lymphoma

tofacitinib has been researched along with Precursor-Cell-Lymphoblastic-Leukemia-Lymphoma* in 1 studies

Other Studies

1 other study(ies) available for tofacitinib and Precursor-Cell-Lymphoblastic-Leukemia-Lymphoma

Article	Year
Failure of tofacitinib to achieve an objective response in a Cold Spring Harbor molecular case studies, 2020, Volume: 6, Issue:4 T-cell lymphoblastic lymphoma/T-cell acute lymphoblastic leukemia (T-LBL/T ALL) is an aggressive hematological malignancy arising from malignant transformation of T-cell progenitors with poor prognosis in adult patients. Outcomes are particularly dismal in the relapsed/refractory setting, and therapeutic options are limited in this context. Genomic profiling has shown frequent aberrations in the JAK-STAT pathway, including recurrent mutations in Topics: Aged; Cell Transformation, Neoplastic; DEAD-box RNA Helicases; Drug Resistance, Neoplasm; Exome Sequencing; Female; Humans; Janus Kinase 1; Janus Kinase 3; Piperidines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Transcription Factors	2020

Article

Year

Failure of tofacitinib to achieve an objective response in a

Cold Spring Harbor molecular case studies, 2020, Volume: 6, Issue:4

T-cell lymphoblastic lymphoma/T-cell acute lymphoblastic leukemia (T-LBL/T ALL) is an aggressive hematological malignancy arising from malignant transformation of T-cell progenitors with poor prognosis in adult patients. Outcomes are particularly dismal in the relapsed/refractory setting, and therapeutic options are limited in this context. Genomic profiling has shown frequent aberrations in the JAK-STAT pathway, including recurrent mutations in

Topics: Aged; Cell Transformation, Neoplastic; DEAD-box RNA Helicases; Drug Resistance, Neoplasm; Exome Sequencing; Female; Humans; Janus Kinase 1; Janus Kinase 3; Piperidines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Transcription Factors

2020